Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. septembre 2022 Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ Monica Bubenik, Pavel Mader, Et Al. Journal of Medicinal Chemistry juillet 2022 Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306 Janek Szychowski, Robert Papp, Et Al. American Chemical Society juillet 2022 Guiding ATR and PARP inhibitor combinationswith chemogenomic screens Zimmermann M, Bernier C, Et Al. Cell Reports avril 2022 CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition Gallo D, Young JTF, Fourtounis J, et al. Nature février 2022 RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors Roulston A, Zimmermann M, Papp R, et al. Molecular Cancer Therapeutics juin 2020 Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity Sokolova AO, Yu EY, Cheng HH Clinical Cancer Research mai 2020 Identifying functional loss of ATM gene in patients with advanced cancer Pilie PG, Gheeya JS, Kyewalabye K, et al. ASCO février 2020 Analyse pan-cancer de génomes entiers Consortium ICGC/TCGA pour l'analyse pancancer du génome entier Nature février 2020 Pan-cancer analysis of whole genomes ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Nature janvier 2020 CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions Su D, Feng X, Colic M, et al. ScienceDirect 12 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
